About COMPARE-UF

COMPARE-UF is a nationwide registry of women with uterine fibroids that hopes to answer questions about the outcomes of different treatment options.compare-uf_The-Registry

  • How do different treatments affect the ability to become pregnant, symptoms from uterine fibroids (such as bleeding and pain), and overall quality of life?
  • Are some treatment options better than others for different groups of women?

Each participant will make treatment decisions with her personal doctor, and then share information about her current and past experiences with her fibroids, including how fibroids have impacted her quality of her life.

View the COMPARE-UF Data Collection Summary to see the information that will be asked of participants and obtained from medical records.

The Duke Clinical Research Institute (DCRI) of the Duke University Medical Center in Durham, NC serves as the Research Data and Coordinating Center (RDCC). Dr. Evan Myers is the Principal Investigator of the COMPARE-UF Registry.

Learn more about the people and groups working to make COMPARE-UF a success.

 

compare-uf_study_the-question_


Our Goal

Our aim is to understand which fibroid treatment options are most effective and what factors influence treatment outcomes.

We hope that the information we learn from this registry will help answer those questions so women with uterine fibroids will be able to make informed decisions about their treatment options.


How did we get here?

Uterine fibroid research interest by the Agency for Healthcare Research and Quality (AHRQ) has been ongoing since 1999.

1999-2000 Literature Review
AHRQ-funded systematic literature review by on management of fibroids
Result: almost no data to help patients make decisions. Only definitive conclusion was that hysterectomy is inappropriate for women who wish to retain fertility
2000–2005 Study of Uterine Artery Embolization
Society of Interventional Radiologists, with funding from AHRQ, FDA, and industry, enrolls over 3000 women undergoing uterine artery embolization (UAE), with up to 3 years follow-up by the Duke Clinical Research Institute (DCRI).
2007 Update to Literature Review
AHRQ-funded update on systematic review performed by RTI International.
2010–2011 Priorities Set
AHRQ-funded multi-stakeholder conference for priorities for comparative effectiveness research for fibroids.
2012 Application for Funding
Outcome applied for PCORI funding for analysis of private claims/EMR data, focused primarily on recurrence of symptoms/need for additional treatment.

  • Methodology development
  • Identifying recurrence within administrative data
  • Involving patients in administrative data studies
  • Informing study design for prospective registry
2013 PCORI/Stakeholder Conference

February

  • PCORI conference to develop targeted funding announcement for fibroids
    Many of same stakeholders involved
    Clear message from patient stakeholders—registry preferred to RCT

April

PCORI announced $20 million for registry to be administered by AHRQ.

2013–2014 Request for Application

The Requests for Applications (RFA) timeline

September 30, 2013: RFA released
December 16, 2013: Proposal (paper) submitted
February 25, 2014: Score received (28)
March 5, 2014: Summary Statement
April 27, 2014: Response to reviewers, AHRQ/PCORI questions
May 2014: Updated response
July 2014: Response to second set of questions
September 2014: Response to administrative questions
September 30, 2014: Notice of grant award (NoGA)

2015 - Registry Enrollment Begins
First patients enrolled in the registry in December 2015.